Serum prostate specific antigen levels after transurethral resection of prostate: A longitudinal characterization in men with benign prostatic hyperplasia

Journal of Urology

Volumn 156, Issue 3, 1996, Pages 1035-1039

  Marks, Leonard S ^a   Dorey, Frederick J ^a   Rhodes, Thomas ^a   Shery, Erlinda D ^a   Rittenhouse, Harry ^a   Partin, Alan W ^a   DeKernion, Jean B ^a  

^a NONE

Author keywords

prostate; prostate specific antigen; prostatic hypertrophy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REFERENCE VALUE; TRANSURETHRAL RESECTION;

EID: 0029759006     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65694-5     Document Type: Article

References (33)

1. Stamey, T. A., Kabalin, J. N., McNeal, J. E., Johnstone, I. M., Freiha, F. S., Redwine, E. A. and Yang, N.: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J. Urol., 141: 1076, 1989.
2. Carter, H. B., Partin, A. W., Oesterling, J. E., Weber, J. P., Epstein, J. I., Chan, D. W., Rock, R. C. and Walsh, P. C.: The use of prostate-specific antigen in the management of patients with prostate cancer: the Johns Hopkins experience. In: Clinical Aspects of Prostate Cancer. Edited by W. J. Catalona, D. S. Coffey and J. P. Karr. New York: Elsevier Science Publishing Co., sect. III, pp. 247-251, 1989.
3. Lange, P. H., Ercole, C. J., Lightner, D. J., Fraley, E. E. and Vessella, R.: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol., 141: 873, 1989.
4. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E.: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. New Engl. J. Med., 317: 909, 1987.
5. Lloyd, S. N., Collins, G. N., McKelvie, G. B., Hehir, M. and Rogers, A. C. N.: Predicted and actual change in serum PSA following prostatectomy for BPH. Urology, 43: 472, 1994.
6. Millin, T.: Retropubic prostatectomy: new extravesical technique: report on 20 cases. Lancet, 2: 693, 1945.
7. Nesbit, R. M.: Transurethral Prostatectomy. Springfield, Illinois: Charles C. Thomas, 1943.
8. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
9. Fiore, M., Mitchell, J., Doan, T., Nelson, R., Winter, G., Grandone, C., Zeng, K., Haraden, R., Smith, J. and Harris, K.: The Abbott IMx automated benchtop immunochemistry analyzer system. Clin. Chem., 34: 1726, 1988.
10. Oesterling, J. E., Moyad, M. A., Wright, G. L., Jr. and Beck, G. R.: An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx. Urology, 46: 524, 1995.
11. Jacobsen, S. J., Lilja, H., Klee, G. G., Wright, G. L., Jr., Pettersson, K. and Oesterling, J. E.: Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology, 44: 512, 1994.
12. Carter, H. B., Pearson, J. D., Waclawiw, Z., Metter, E. J., Chan, D. W., Guess, H. A. and Walsh, P. C.: Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology, 45: 591, 1995.
13. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol., 142: 71, 1989.
14. Carter, H. B., Pearson, J. D., Metter, E. J., Brant, L. J., Chan, D. W., Andres, R., Fozard, J. L. and Walsh, P. C.: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. J.A.M.A., 267: 2215, 1992.
15. Schmid, H. P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 15: 2031, 1993.
16. Haab, F., Meulemans, A., Boccon-Gibod, L., Dauge, M. C., Delmas, V. and Boccon-Gibod, L.: Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate, 26: 334, 1995.
17. McNeal, J. E.: The prostate gland: morphology and pathobiology. Monogr. Urol., 9: 36, 1988.
18. Lepor, H., Wang, B. and Shapiro, E.: Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology, 44: 199, 1994.
19. Hammerer, P. G., McNeal, J. E. and Stamey, T. A.: Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J. Urol., 153: 111, 1995.
20. Cadeddu, J. A., Pearson, J. D., Lee, B. R., Landis, P., Partin, A. W., Epstein, J. I. and Carter, H. B.: Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology, 45: 795, 1995.
21. Tempany, C. M., Partin, A. W., Zerhouni, E. A., Zinreich, S. J. and Walsh, P. C.: The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate, 22: 39, 1993.
22. Tewari, A., Shinohara, K. and Narayan, P.: Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology, 45: 258, 1995.
23. Guess, H. A., Gormley, G. J., Stoner, E. and Oesterling, J. E.: The effect of finasteride on prostate specific antigen: review of available data. J. Urol., 155: 3, 1996.
24. Stamey, T. A., Dietrick, D. D. and Issa, M. M.: Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. J. Urol., 149: 510, 1993.
25. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
26. Benson, M. C., Whang, I. S., Pantuck, A., Ring, K., Kaplan, S. A., Olsson, C. A. and Cooner, W. H.: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol., 147: 815, 1992.
27. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K. and Alfthan, O.: A complex between prostate-specific antigen and alphal-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res., 51: 222, 1991.
28. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B. and Ng, J.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. J. Med., 327: 1185, 1992.
29. Lepor, H., Meretyk, S. and Knapp-Maloney, G.: The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia. J. Urol., 147: 1554, 1992.
30. National Hospital Discharge Survey data tapes. Hyattsville, Maryland: National Center for Health Statistics, 1986-1992.
31. Mebust, W. K., Holtgrewe, H. L., Cockett, A. T. K. and Peters, P. C.: Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J. Urol., 141: 243, 1989.
32. National Center for Health Statistics: Vital Statistics of the United States, 1986, Vol. II, Mortality. Washington, D. C.: United States Government Printing Office, 1986.
33. Greenwald, P., Kirmss, V., Polan, A. K. and Dick, V. S.: Cancer of the prostate among men with benign prostatic hyperplasia. J. Natl. Cancer Inst., 53: 335, 1974.